Clinical Omics – News and Features

Collaboration aims to develop workflows to overcome current bottlenecks in biomarker discovery and assay development for clinical proteomics research.

Keynote speakers include Dr. James Watson, Dr. Todd Golub and Ms. Linette Granen.

Accelerating biomarker identification for cancer and other diseases may speed development of diagnostic tests that enable earlier disease detection.

More than $400,000 in RNAi screening tools awarded to advance biomedical research and drug discovery.

Precision Antibody™ has been selected as the antibody developer for a component of the National Cancer Institute (NCI)’s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.

The collaboration will combine AFG’s SISCAPA technology with Agilent’s HPLC-Chip and triple quadrupole MS to speed protein biomarker discovery and validation.

The study shows that an enzyme known to play a major role in lipid production was highly elevated in human liver cells exposed to the hepatitis C virus.

Data demonstrate that the biomarker signature may enable a much earlier prediction of drug-induced kidney toxicity during pre-clinical trials.

BGI and PentaBase plan to co-develop Real-Time PCR kits for the detection of important clinical biomarkers.

The collaboration unites Agilent’s suite of solutions for proteomics, genomics and metabolomics with the scientific and diagnostic expertise of scientists at the center.